Clinical Trial Update: BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on BCMA-CD19 CAR-T therapy for refractory autoimmune diseases, currently recruiting. The study targets several autoimmune conditio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura
• Anca-associated Vasculitis
• Antiphospholipid Syndrome
• Behcet Disease
• Igg4-related Diseases
• Sjogren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• BCMA-CD19 CAR-T therapy (BCMA-CD19 CAR-T)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Status: RECRUITING